Fennel Oil/Foeniculum vulgare / cycD1/CCND1 Cancer Research Results

FEO, Fennel Oil/Foeniculum vulgare: Click to Expand ⟱
Features:

fennel essential oil has major constituents commonly include trans-anethole, fenchone, estragole, limonene, and cis-anethole, and the proportions vary substantially by source, geography, and chemotype. One composition study found trans-anethole ranging 34.8–82.0%, fenchone 1.6–22.8%, estragole 2.4–17.0%, and limonene 0.8–16.5%. Another study found even wider variation, with estragole(toxic) reported up to 66% in some fennel oils.

Fennel oil — the volatile essential oil distilled primarily from the ripe fruits of Foeniculum vulgare Mill. It is a variable botanical mixture rather than a single pharmacological agent and is formally classified as a plant-derived essential oil or phytochemical mixture. Standard abbreviations include FEO and FVO. Trans-anethole is usually the dominant constituent, with fenchone, estragole, limonene, α-pinene and smaller terpenoids present in chemotype-dependent proportions. Sweet fennel oil is generally richer in trans-anethole and lower in fenchone than bitter fennel oil. Biological effects cannot be assigned uniformly across products because constituent concentrations, especially estragole, vary substantially.

Primary mechanisms (ranked):

  1. Mitochondrial and lysosomal membrane disruption with Bax/Bcl-2 shifting, caspase-9 and caspase-3 activation, PARP cleavage and apoptotic cell death, principally demonstrated for trans-anethole and selected fennel-oil preparations.
  2. Suppression of NF-κB-dependent survival and inflammatory signaling, including inhibition of TNF-induced NF-κB activation and downstream anti-apoptotic responses.
  3. Inhibition of cancer-cell proliferation through cell-cycle arrest and reduced clonogenic or tumorsphere-forming capacity.
  4. ROS elevation and oxidative stress in susceptible cancer cells, contributing to DNA damage, mitochondrial permeabilization, apoptosis and, in some models, autophagy.
  5. Suppression of migration, invasion and cancer stem-like phenotypes in prostate, breast and oral cancer models.
  6. Chemosensitization to cisplatin in preclinical models through increased apoptosis and reduced survival signaling.
  7. Anti-inflammatory and antioxidant effects in non-malignant tissues, including reduced inflammatory cytokine signaling; these effects are context-dependent and may oppose the pro-oxidant mechanism observed in cancer cells.

Bioavailability / PK relevance: Fennel oil is lipophilic, volatile and compositionally variable. Trans-anethole is absorbed and extensively metabolized by side-chain oxidation, with urinary elimination dominated by 4-methoxyhippuric acid. At low dietary exposures, detoxification predominates; high continuous exposures can shift metabolism toward potentially hepatotoxic intermediates. Oral anticancer exposure, tumor distribution and a validated therapeutic plasma concentration have not been established. Encapsulation may improve stability and delivery, but remains experimental.

In-vitro vs systemic exposure relevance: Most anticancer findings use concentrated essential oil or trans-anethole at micromolar concentrations, often approximately 50–200 µM, or essential-oil concentrations measured in µg/mL. These exposures are substantially higher than ordinary dietary exposure and have not been shown to be safely achievable in human tumors. Fennel tea, culinary seed intake and aromatherapy should not be treated as pharmacokinetically equivalent to concentrated essential oil.

Clinical evidence status: Preclinical only for cancer treatment. Evidence consists mainly of cancer-cell studies, limited animal experiments and mechanistic studies of trans-anethole. There are no established randomized oncology trials, approved anticancer indications or validated clinical dosing regimens for fennel oil. Traditional herbal deployment is directed mainly toward mild gastrointestinal or respiratory symptoms rather than cancer. Concentrated internal use is constrained by estragole exposure, product heterogeneity, allergy risk and inadequate long-term safety data.

Fennel Oil Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipophilic membrane stress Viability ↓; membrane integrity ↓; morphology altered Potential membrane irritation at high exposure G Weak-to-moderate cytotoxicity Core essential-oil mechanism; requires high in-vitro concentrations and depends strongly on oil composition.
2 Mitochondrial ROS and oxidative stress signaling ROS ↑; JNK/c-Jun ↑; stress proteins ↑ Antioxidant or anti-inflammatory effects may occur in non-cancer models R/G Stress-amplified apoptosis Most convincing in TNBC cell data using Foeniculum vulgare subsp. piperitum oil; antioxidant rescue supports ROS involvement.
3 NRF2 stress-response activation NRF2 ↑; HO-1 ↑; NQO1 ↑ Potential cytoprotection ↑ (context-dependent) G Adaptive stress response plus apoptosis coupling In cancer cells, NRF2 activation appears secondary to ROS stress and coexists with apoptosis; not necessarily a purely protective effect.
4 p53 DNA damage apoptosis axis p53-axis ↑; γH2AX ↑; caspase-3 ↑; PARP cleavage ↑ Genotoxic-risk concern if estragole exposure is substantial G Apoptotic cell death Mechanistically relevant for anticancer interpretation, but safety interpretation is complicated by DNA-reactive estragole metabolism.
5 Cell-cycle and proliferation markers Cell-cycle arrest ↑; Ki-67 ↓; Bcl-2 ↓; miR-21 ↓; miR-92a ↓ Limited toxicity in tested lymphocytes in one oil-mixture model G Growth arrest and apoptosis Evidence is partly from fennel plus geranium oil mixtures, so attribution to fennel oil alone is uncertain.
6 Survivin mitochondrial apoptosis axis Survivin ↓; mitochondrial toxicity ↑; caspase-3 ↑ Normal liver-cell toxicity ↔ in seed-extract model G Apoptosis sensitization Relevant to Foeniculum vulgare seed extract rather than essential oil specifically; useful as genus-level support but not direct FEO evidence.
7 Inflammatory cytokine suppression Indirect tumor relevance only IL-6 ↓; TNF-α ↓; IL-1β ↓; inflammation ↓ G Anti-inflammatory modulation Better supported in normal inflammatory models than in tumor microenvironment models.
8 TRPA1 activation Unclear; context-dependent Ca²⁺ signaling possible TRPA1 ↑; sensory/neurogenic signaling possible R Ion-channel agonism Mechanistically specific for trans-anethole, but not yet a primary anticancer axis for fennel oil.
9 Estragole bioactivation and genotoxicity DNA adduct risk ↑; carcinogenic liability ↑ DNA-reactive metabolite risk ↑ G Safety constraint This is a negative translational feature. Estragole-rich oils should not be interpreted as desirable anticancer products.
10 Clinical Translation Constraint High in-vitro concentrations; chemotype heterogeneity; no oncology RCTs Estragole exposure, irritation, sensitization, pregnancy and pediatric constraints G Limits clinical relevance For database purposes, FEO should be marked preclinical and composition-dependent, with estragole content as a required safety note.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
Scientific Papers found: Click to Expand⟱
6396- ANE,  FEO,    Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis
- in-vitro, Pca, PC3
TumCP↓, TumCG↓, TumCMig↓, CSCs↓, ROS↑, MPT↑, Casp3↑, Casp9↑, DNAdam↑, cl‑PARP↑, Bax:Bcl2↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, cMyc↓, P21↑, p27↑, NF-kB↓, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MPT↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

Bax:Bcl2↑, 1,   Casp3↑, 1,   Casp9↑, 1,   p27↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

TumCMig↓, 1,   TumCP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  
Total Targets: 19

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:404  Target#:73  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page